Immunolocalisation and imaging of small cell cancer xenografts by the IgG2a monoclonal antibody SWA11

Smith, Alan Р.; Waibel, Robert; Westera, G.; Martin, A. J. P.; Zimmerman, Asha; Stahel, R.

doi:10.1038/bjc.1989.36

Cited by 36 publications

(31 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several of these have been grouped into clusters defined by two international workshops on the basis of a common pattern of reactivity (Souhami et al, , 1991. Radiolabelled antibodies against clusters 1 and w4 have been shown to localise SCLC growing as a xenograft in 'nude mice' (Yoneda et al, 1988;Smith et al, 1989;Wilson et al, 1990;Boerman et al, 1991) (Sutherland & Durand, 1984) and they have been used as a model to compare the microdistribution of different anti-tumour antibodies (Sutherland et al, 1987) and to evaluate targeted radiotherapy (Gaze et al, 1992).…”

mentioning

confidence: 99%

See 1 more Smart Citation

The selection of antibodies for targeted therapy of small-cell lung cancer (SCLC) using a human tumour spheroid model to compare the uptake of cluster 1 and cluster w4 antibodies

Olabiran

Ledermann²,

Marston³

et al. 1994

Br J Cancer

Self Cite

View full text Add to dashboard Cite

Summary Spheroids of a small-cell lung cancer (SCLC) cell line POC were used to evaluate the uptake and penetration of two antibodies recognising different SCLC antigens. Spheroids approximately 300-400 gm in diameter were incubated with 1 jig ml-"25I-labelled NY.3DI 1, an antibody which reacts with the cluster I group antigen (neural cell adhesion molecule; NCAM) and ['25I]SWAI 1, which binds to the cluster w4 antigen. The rate of uptake of both antibodies was similar; an initially rapid phase was seen during the first 8 h and maximum uptake occurred by 24 h. This increased to about 100 txm after 4 h incubation with I or 100 fig ml-' SWAI 1. The results with I lg mlh' NY.3D1 were similar, but in the presence of 100 jg ml-' NY.3DI I penetration into the spheroid was deep and diffuse. These results demonstrate a major concentration-dependent difference in the uptake and penetration of cluster I and cluster w4 antibodies in this spheroid model and they have implications for the selection of antibodies for targeted therapy of SCLC.

show abstract

mentioning

confidence: 99%

“…One antibody is directed against the cluster 1 antigen, the neural cell adhesion molecule (NCAM) (Patel et al, 1989) expressed on SCLC, and the other is against the cluster w4 antigen (Smith et al, 1989), which has recently been shown to be identical to a leucocyte activation antigen CD24 (Jackson et al, 1992).…”

mentioning

confidence: 99%

The selection of antibodies for targeted therapy of small-cell lung cancer (SCLC) using a human tumour spheroid model to compare the uptake of cluster 1 and cluster w4 antibodies

Olabiran

Ledermann²,

Marston³

et al. 1994

Br J Cancer

Self Cite

View full text Add to dashboard Cite

show abstract

“…Preclinical studies demonstrated that SWA 11 bound to granulocytes, but with a much lower affinity than to SCLC cells (Smith et al, 1989). We proceeded with a clinical study as it was unclear whether the interaction of SWAl1 with granulocytes would impair tumour targeting in man, and because of the encouraging results of therapy with "3'I SWAl1 in animals .…”

Section: Discussionmentioning

confidence: 99%

“…Antibody SWAI1, a mouse IgG2a monoclonal antibody was produced as previously described (Smith et al, 1989 (Operation manual, 1986). One milligram of antibody was conjugated to approximately 5 mCi of "'1I using chloramine T. Over 90% of the radioactivity was incorporated into protein and a cell binding assay using a human SCLC cell line, UCH1O showed that there was preservation of antigen binding after radiolabelling.…”

Section: Methodsmentioning

confidence: 99%

“…SWAI1 binds to some adenocarcinomas, carcinoid tumours and ductal epithelia. The antibody also binds weakly to a subpopulation of human granulocytes (Smith et al, 1989). Radiolabelled SWAl1 has been shown to localise specifically in SCLC tumours growing as xenografts in nude mice and intravenous injections of therapeutic doses of 131I SWAl1 have eradicated SCLC xenografts in mice , Smith et al, 1989.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Biodistribution and tumour localisation of 131I SWA11 recognising the cluster w4 antigen in patients with small cell lung cancer

Ledermann

Marston²,

Stahel³

et al. 1993

Br J Cancer

Self Cite

View full text Add to dashboard Cite

Summary The biodistribution of radiolabelled SWAl 1, a mouse monoclonal antibody recognising the cluster w4 group antigen associated with small cell lung cancer (SCLC) was studied in patients with SCLC. Five patients were injected intravenously with approximately 5 mCi of '31I conjugated to I mg of SWA II. The half-life of the radiolabel in blood was short but there was a prolonged second phase of clearance with a half-life of about 40 h. Tumour was detected by gamma camera imaging two patients. However, most of the whole body radioactivity was located in the bone marrow. At least 35% of the radioactivity in blood 18 h after injection was bound to circulating granulocytes and this probably accounted for the unusual biodistribution of the radiolabel in man. This study shows that the biodistribution of radiolabelled SWA 11 in man differs from human tumour xenograft models and that the antibody in unsuitable for targeting therapy to SCLC in man.

show abstract

Potent anti-tumor effects of an anti-CD24 ricin A-chain immunotoxinin vitro and in a disseminated human Burkitt's lymphoma model in SCID mice

et al. 1996

View full text Add to dashboard Cite

show abstract

Immunolocalisation and imaging of small cell cancer xenografts by the IgG2a monoclonal antibody SWA11

Cited by 36 publications

References 12 publications

The selection of antibodies for targeted therapy of small-cell lung cancer (SCLC) using a human tumour spheroid model to compare the uptake of cluster 1 and cluster w4 antibodies

The selection of antibodies for targeted therapy of small-cell lung cancer (SCLC) using a human tumour spheroid model to compare the uptake of cluster 1 and cluster w4 antibodies

Biodistribution and tumour localisation of 131I SWA11 recognising the cluster w4 antigen in patients with small cell lung cancer

Potent anti-tumor effects of an anti-CD24 ricin A-chain immunotoxinin vitro and in a disseminated human Burkitt's lymphoma model in SCID mice

Contact Info

Product

Resources

About